Compare Biocon Ltd with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs DR. REDDYS LAB - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the pharmaceutical value chain - basic research, finished dosages, generics, bulk actives, and biotechnology. The company's business is mainly organized into Global g... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON DR. REDDYS LAB BIOCON /
DR. REDDYS LAB
 
P/E (TTM) x 30.5 32.2 94.9% View Chart
P/BV x 3.9 4.5 87.1% View Chart
Dividend Yield % 0.3 0.5 47.8%  

Financials

 BIOCON    DR. REDDYS LAB
EQUITY SHARE DATA
    BIOCON
Mar-19
DR. REDDYS LAB
Mar-19
BIOCON /
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs7072,875 24.6%   
Low Rs5541,888 29.3%   
Sales per share (Unadj.) Rs91.9930.2 9.9%  
Earnings per share (Unadj.) Rs16.7117.4 14.2%  
Cash flow per share (Unadj.) Rs24.2185.8 13.0%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.20.8 18.9%  
Book value per share (Unadj.) Rs101.6844.4 12.0%  
Shares outstanding (eoy) m600.00166.07 361.3%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x6.92.6 268.0%   
Avg P/E ratio x37.720.3 186.1%  
P/CF ratio (eoy) x26.112.8 203.5%  
Price / Book Value ratio x6.22.8 220.0%  
Dividend payout %6.017.0 35.1%   
Avg Mkt Cap Rs m378,330395,496 95.7%   
No. of employees `0006.122.0 27.9%   
Total wages/salary Rs m11,65333,562 34.7%   
Avg. sales/employee Rs Th8,994.37,032.8 127.9%   
Avg. wages/employee Rs Th1,900.71,527.9 124.4%   
Avg. net profit/employee Rs Th1,635.3887.7 184.2%   
INCOME DATA
Net Sales Rs m55,144154,482 35.7%  
Other income Rs m1,4443,375 42.8%   
Total revenues Rs m56,588157,857 35.8%   
Gross profit Rs m15,88331,782 50.0%  
Depreciation Rs m4,47811,348 39.5%   
Interest Rs m709889 79.8%   
Profit before tax Rs m12,14022,920 53.0%   
Minority Interest Rs m90-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2,1233,858 55.0%   
Profit after tax Rs m10,02619,500 51.4%  
Gross profit margin %28.820.6 140.0%  
Effective tax rate %17.516.8 103.9%   
Net profit margin %18.212.6 144.0%  
BALANCE SHEET DATA
Current assets Rs m48,228111,101 43.4%   
Current liabilities Rs m30,37658,973 51.5%   
Net working cap to sales %32.433.7 95.9%  
Current ratio x1.61.9 84.3%  
Inventory Days Days6879 86.1%  
Debtors Days Days8694 90.8%  
Net fixed assets Rs m64,130101,245 63.3%   
Share capital Rs m3,000830 361.4%   
"Free" reserves Rs m57,980139,406 41.6%   
Net worth Rs m60,980140,236 43.5%   
Long term debt Rs m15,76622,000 71.7%   
Total assets Rs m121,924224,656 54.3%  
Interest coverage x18.126.8 67.7%   
Debt to equity ratio x0.30.2 164.8%  
Sales to assets ratio x0.50.7 65.8%   
Return on assets %8.89.1 97.0%  
Return on equity %16.413.9 118.2%  
Return on capital %16.814.9 112.1%  
Exports to sales %28.10-   
Imports to sales %18.90-   
Exports (fob) Rs m15,506NA-   
Imports (cif) Rs m10,399NA-   
Fx inflow Rs m15,50688,673 17.5%   
Fx outflow Rs m10,39919,104 54.4%   
Net fx Rs m5,10769,569 7.3%   
CASH FLOW
From Operations Rs m11,54628,704 40.2%  
From Investments Rs m-7,138-7,727 92.4%  
From Financial Activity Rs m-2,417-21,326 11.3%  
Net Cashflow Rs m2,103-314 -669.7%  

Share Holding

Indian Promoters % 40.4 25.5 158.4%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 5.4 155.6%  
FIIs % 10.7 35.3 30.3%  
ADR/GDR % 0.0 18.5 -  
Free float % 19.9 15.3 130.1%  
Shareholders   109,995 75,885 144.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   CIPLA  PFIZER  NATCO PHARMA  SHASUN PHARMA  SANOFI INDIA  

Compare BIOCON With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Upcoming IPOs, Bajaj Finance June Quarter Numbers, and Top Buzzing Stocks Today(Pre-Open)

Extending gains to the fifth consecutive session, Indian share markets witnessed volatile trading activity throughout the day yesterday and ended higher.

Related Views on News

BIOCON Announces Quarterly Results (3QFY20); Net Profit Up 1.2% (Quarterly Result Update)

Jan 24, 2020 | Updated on Jan 24, 2020

For the quarter ended December 2019, BIOCON has posted a net profit of Rs 2 bn (up 1.2% YoY). Sales on the other hand came in at Rs 17 bn (up 13.5% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

BIOCON Announces Quarterly Results (4QFY19); Net Profit Down 53.8% (Quarterly Result Update)

Apr 26, 2019 | Updated on Apr 26, 2019

For the quarter ended March 2019, BIOCON has posted a net profit of Rs 705 m (down 53.8% YoY). Sales on the other hand came in at Rs 8 bn (down 34.7% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Be Prepared to Profit from the Coming Crash in Oil Prices(Fast Profits Daily)

Jun 25, 2020

The stability in crude oil prices will not last much longer. Be ready to make fast profits when the time comes to short crude.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Jul 7, 2020 (Close)

TRACK BIOCON

BIOCON - VENUS REMEDIES COMPARISON

COMPARE BIOCON WITH

MARKET STATS